Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2015, Article ID 496169, 18 pages
http://dx.doi.org/10.1155/2015/496169
Review Article

Beneficial Role of Bitter Melon Supplementation in Obesity and Related Complications in Metabolic Syndrome

1Department of Pharmaceutical Sciences, North South University, Dhaka 1229, Bangladesh
2Department of Pharmacy, Stamford University Bangladesh, Dhaka 1217, Bangladesh
3School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia

Received 30 August 2014; Accepted 5 December 2014

Academic Editor: Xian-Cheng Jiang

Copyright © 2015 Md Ashraful Alam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kelly, W. Yang, C.-S. Chen, K. Reynolds, and J. He, “Global burden of obesity in 2005 and projections to 2030,” International Journal of Obesity, vol. 32, no. 9, pp. 1431–1437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. M. Finucane, G. A. Stevens, M. J. Cowan et al., “National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants,” The Lancet, vol. 377, no. 9765, pp. 557–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Kanter and B. Caballero, “Global gender disparities in obesity: a review,” Advances in Nutrition, vol. 3, no. 4, pp. 491–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. W. Kimokoti and B. E. Millen, “Diet, the global obesity epidemic, and prevention,” Journal of the American Dietetic Association, vol. 111, no. 8, pp. 1137–1140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Power and J. Schulkin, “Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins,” British Journal of Nutrition, vol. 99, no. 5, pp. 931–940, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. B. M. Herrera, S. Keildson, and C. M. Lindgren, “Genetics and epigenetics of obesity,” Maturitas, vol. 69, no. 1, pp. 41–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. WHO, The World Health Report. Reducing Risks Promoting Healthy Life, World Health Organization, Geneva, Switzerland, 2002.
  8. D. P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C. L. Birmingham, and A. H. Anis, “The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis,” BMC Public Health, vol. 9, article 88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Ibrahim, “Subcutaneous and visceral adipose tissue: structural and functional differences,” Obesity Reviews, vol. 11, no. 1, pp. 11–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Hoffstedt, E. Arner, H. Wahrenberg et al., “Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity,” Diabetologia, vol. 53, no. 12, pp. 2496–2503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. S. Hotamisligil and B. M. Spiegelman, “Tumor necrosis factor α: a key component of the obesity-diabetes link,” Diabetes, vol. 43, no. 11, pp. 1271–1278, 1994. View at Google Scholar · View at Scopus
  12. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. F. I. Milagro, J. Campión, and J. A. Martíez, “Weight gain induced by high-fat feeding involves increased liver oxidative stress,” Obesity, vol. 14, no. 7, pp. 1118–1123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Shoelson, L. Herrero, and A. Naaz, “Obesity, inflammation, and insulin resistance,” Gastroenterology, vol. 132, no. 6, pp. 2169–2180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Abedini and S. E. Shoelson, “Inflammation and obesity: STAMPing out insulin resistance?” Immunology & Cell Biology, vol. 85, no. 6, pp. 399–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. C. Arkan, A. L. Hevener, F. R. Greten et al., “IKK-β links inflammation to obesity-induced insulin resistance,” Nature Medicine, vol. 11, no. 2, pp. 191–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Leuenberger and W. Wahli, “PPARα, A key regulator of hepatic energy homeostasis in health and disease,” in Signaling Pathways in Liver Diseases, J. F. Dufour and P. A. Clavien, Eds., pp. 305–315, Springer, Berlin, Germany, 2010. View at Google Scholar
  19. N. Venteclef, T. Jakobsson, K. R. Steffensen, and E. Treuter, “Metabolic nuclear receptor signaling and the inflammatory acute phase response,” Trends in Endocrinology and Metabolism, vol. 22, no. 8, pp. 333–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Bensinger and P. Tontonoz, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” Nature, vol. 454, no. 7203, pp. 470–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-D. Wang, W.-D. Chen, D. D. Moore, and W. Huang, “FXR: a metabolic regulator and cell protector,” Cell Research, vol. 18, no. 11, pp. 1087–1095, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Chinetti-Gbaguidi, J.-C. Fruchart, and B. Staels, “Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy,” Current Opinion in Pharmacology, vol. 5, no. 2, pp. 177–183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Wenz, “PGC-1α activation as a therapeutic approach in mitochondrial disease,” IUBMB Life, vol. 61, no. 11, pp. 1051–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. López-Lluch, P. M. Irusta, P. Navas, and R. de Cabo, “Mitochondrial biogenesis and healthy aging,” Experimental Gerontology, vol. 43, no. 9, pp. 813–819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Pilegaard, B. Saltin, and D. P. Neufer, “Exercise induces transient transcriptional activation of the PGC-1α gene in human skeletal muscle,” The Journal of Physiology, vol. 546, no. 3, pp. 851–858, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. V. A. Lira, C. R. Benton, Z. Yan, and A. Bonen, “PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 299, no. 2, pp. E145–E161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. C. Corton and H. M. Brown-Borg, “Peroxisome proliferator-activated receptor γ coactivator 1 in caloric restriction and other models of longevity,” The Journals of Gerontology, vol. 60, no. 12, pp. 1494–1509, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Bastin, F. Aubey, A. Rötig, A. Munnich, and F. Djouadi, “Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1433–1441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Choi, H. Eo, K. Park et al., “A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model,” Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 419–425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. H. Park, S. K. Ko, and S. H. Chung, “Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice,” Journal of Ethnopharmacology, vol. 102, no. 3, pp. 326–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Ikarashi, T. Toda, T. Okaniwa, K. Ito, W. Ochiai, and K. Sugiyama, “Anti-obesity and anti-diabetic effects of Acacia polyphenol in obese diabetic KKAy mice fed high-fat diet,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 952031, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Nagao, Y. Komine, S. Soga et al., “Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 122–129, 2005. View at Google Scholar · View at Scopus
  34. M. B. Krawinkel and G. B. Keding, “Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia,” Nutrition Reviews, vol. 64, no. 7, pp. 331–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. K. Grover and S. P. Yadav, “Pharmacological actions and potential uses of Momordica charantia: a review,” Journal of Ethnopharmacology, vol. 93, no. 1, pp. 123–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. Khan and A. D. Omoloso, “Momordica charantia and Allium sativum: broad spectrum antibacterial activity,” Korean Journal of Pharmacognosy, vol. 29, no. 3, pp. 155–158, 1998. View at Google Scholar · View at Scopus
  37. S. Lee-Huang, P. L. Huang, H.-C. Chen et al., “Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon,” Gene, vol. 161, no. 2, pp. 151–156, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Raman and C. Lau, “Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae),” Phytomedicine, vol. 2, no. 4, pp. 349–362, 1996. View at Publisher · View at Google Scholar
  39. J. Kubola and S. Siriamornpun, “Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro,” Food Chemistry, vol. 110, no. 4, pp. 881–890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Horax, N. Hettiarachchy, and S. Islam, “Total phenolic contents and phenolic acid constituents in 4 varieties of bitter melons (Momordica charantia) and antioxidant activities of their extracts,” Journal of Food Science, vol. 70, no. 4, pp. C275–C280, 2005. View at Google Scholar · View at Scopus
  41. R. Horax, N. Hettiarachchy, and P. Chen, “Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (Immature, Mature, and Ripe),” Journal of Agricultural and Food Chemistry, vol. 58, no. 7, pp. 4428–4433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C.-I. Chang, C.-R. Chen, Y.-W. Liao, H.-L. Cheng, Y.-C. Chen, and C.-H. Chou, “Cucurbitane-type triterpenoids from Momordica charantia,” Journal of Natural Products, vol. 69, no. 8, pp. 1168–1171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. C.-I. Chang, C.-R. Chen, Y.-W. Liao, H.-L. Cheng, Y.-C. Chen, and C.-H. Chou, “Cucurbitane-type triterpenoids from the stems of Momordica charantia,” Journal of Natural Products, vol. 71, no. 8, pp. 1327–1330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Kimura, T. Akihisa, N. Yuasa et al., “Cucurbitane-type triterpenoids from the fruit of Momordica charantia,” Journal of Natural Products, vol. 68, no. 5, pp. 807–809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Pitipanapong, S. Chitprasert, M. Goto, W. Jiratchariyakul, M. Sasaki, and A. Shotipruk, “New approach for extraction of charantin from Momordica charantia with pressurized liquid extraction,” Separation and Purification Technology, vol. 52, no. 3, pp. 416–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-C. Chen, W.-Q. Liu, L. Lu et al., “Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia,” Phytochemistry, vol. 70, no. 1, pp. 133–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Nakamura, T. Murakami, J. Nakamura, H. Kobayashi, H. Matsuda, and M. Yoshikawa, “Structures of new cucurbitane-type triterpenes and glycosides, karavilagenins and karavilosides, from the dried fruit of Momordica charantia L. in Sri Lanka,” Chemical & Pharmaceutical Bulletin, vol. 54, no. 11, pp. 1545–1550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Akihisa, N. Higo, H. Tokuda et al., “Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects,” Journal of Natural Products, vol. 70, no. 8, pp. 1233–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. N. X. Nhiem, P. V. Kiem, C. V. Minh et al., “Cucurbitane-type triterpene glycosides from the fruits of Momordica charantia,” Magnetic Resonance in Chemistry, vol. 48, no. 5, pp. 392–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Q.-Y. Li, H.-B. Chen, Z.-M. Liu, B. Wang, and Y.-Y. Zhao, “Cucurbitane triterpenoids from Momordica charantia,” Magnetic Resonance in Chemistry, vol. 45, no. 6, pp. 451–456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Ma, P. Whittaker, A. C. Keller et al., “Cucurbitane-type triterpenoids from Momordica charantia,” Planta Medica, vol. 76, no. 15, pp. 1758–1761, 2010. View at Publisher · View at Google Scholar
  52. L. Harinantenaina, M. Tanaka, S. Takaoka et al., “Momordica charantia constituents and antidiabetic screening of the isolated major compounds,” Chemical and Pharmaceutical Bulletin, vol. 54, no. 7, pp. 1017–1021, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Liu, Z. Ali, and I. A. Khan, “Cucurbitane-type triterpene glycosides from the fruits of Momordica charantia,” Planta Medica, vol. 74, no. 10, pp. 1291–1294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Murakami, A. Emoto, H. Matsuda, and M. Yoshikawa, “Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L,” Chemical and Pharmaceutical Bulletin, vol. 49, no. 1, pp. 54–63, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. J.-Q. Cao, B.-Y. Zhang, and Y.-Q. Zhao, “A new cucurbitane triterpene in acid-treated ethanol extract from Momordica charantia,” Chinese Herbal Medicines, vol. 5, no. 3, pp. 234–236, 2013. View at Google Scholar
  56. J.-Q. Liu, J.-C. Chen, C.-F. Wang, and M.-H. Qiu, “New cucurbitane triterpenoids and steroidal glycoside from Momordica charantia,” Molecules, vol. 14, no. 12, pp. 4804–4813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. W.-J. He, L. Y. Chan, R. J. Clark et al., “Novel inhibitor cystine knot peptides from Momordica charantia,” PLoS ONE, vol. 8, no. 10, Article ID e75334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. Q. Chen and E. T. S. Li, “Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines,” British Journal of Nutrition, vol. 93, no. 5, pp. 747–754, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. C.-C. Shih, C.-H. Lin, and W.-L. Lin, “Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet,” Diabetes Research and Clinical Practice, vol. 81, no. 2, pp. 134–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Bano, N. Akthar, and H. Naz, “Effect of the aqueous extracts of Momordica charantia on body weight of rats,” Journal of Basic and Applied Sciences, vol. 7, pp. 1–5, 2011. View at Google Scholar
  61. P.-H. Chen, G.-C. Chen, M.-F. Yang et al., “Bitter melon seed oil-attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue,” The Journal of Nutrition, vol. 142, no. 7, pp. 1197–1204, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. L. Y. Chan, Q. Chen, A. G. G. Go, E. K. Y. Lam, and E. T. S. Li, “Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression,” Journal of Nutrition, vol. 135, no. 11, pp. 2517–2523, 2005. View at Google Scholar · View at Scopus
  63. H.-L. Huang, Y.-W. Hong, Y.-H. Wong et al., “Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats,” British Journal of Nutrition, vol. 99, no. 2, pp. 230–239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. D. G. Popovich, L. Li, and W. Zhang, “Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells,” Food and Chemical Toxicology, vol. 48, no. 6, pp. 1619–1626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. P. V. Nerurkar, Y.-K. Lee, and V. R. Nerurkar, “Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes,” BMC Complementary and Alternative Medicine, vol. 10, article 34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. A. P. Jayasooriya, M. Sakono, C. Yukizaki, M. Kawano, K. Yamamoto, and N. Fukuda, “Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets,” Journal of Ethnopharmacology, vol. 72, no. 1-2, pp. 331–336, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. I. Ahmed, M. S. Lakhani, M. Gillett, A. John, and H. Raza, “Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats,” Diabetes Research and Clinical Practice, vol. 51, no. 3, pp. 155–161, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Chaturvedi, S. George, M. Milinganyo, and Y. B. Tripathi, “Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats,” Phytotherapy Research, vol. 18, no. 11, pp. 954–956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Oishi, T. Sakamoto, H. Udagawa et al., “Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction,” Bioscience, Biotechnology, and Biochemistry, vol. 71, no. 3, pp. 735–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. P. V. Nerurkar, Y. K. Lee, M. Motosue, K. Adeli, and V. R. Nerurkar, “Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions,” British Journal of Nutrition, vol. 100, no. 4, pp. 751–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Chaturvedi and S. George, “Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load,” Journal of Medicinal Food, vol. 13, no. 3, pp. 520–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. R. H. H. Ching, L. O. Y. Yeung, I. M. Y. Tse, W.-H. Sit, and E. T. S. Li, “Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring,” Journal of Nutrition, vol. 141, no. 9, pp. 1664–1672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. V. Gadang, W. Gilbert, N. Hettiararchchy, R. Horax, L. Katwa, and L. Devareddy, “Dietary bitter melon seed increases peroxisome proliferator-activated receptor-γ gene expression in adipose tissue, down-regulates the nuclear factor-κB expression, and alleviates the symptoms associated with metabolic syndrome,” Journal of Medicinal Food, vol. 14, no. 1-2, pp. 86–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Yu, X. H. Zhang, B. Ebersole, D. Ribnicky, and Z. Q. Wang, “Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice,” Scientific Reports, vol. 3, article 3142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Matsui, T. Yamane, T. Takita, Y. Oishi, and K. Kobayashi-Hattori, “The hypocholesterolemic activity of Momordica charantia fruit is mediated by the altered cholesterol- and bile acid-regulating gene expression in rat liver,” Nutrition Research, vol. 33, no. 7, pp. 580–585, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. C.-C. Shih, M.-T. Shlau, C.-H. Lin, and J.-B. Wu, “Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice,” Phytotherapy Research, vol. 28, no. 3, pp. 363–371, 2014. View at Publisher · View at Google Scholar
  77. N. Ahmad, M. R. Hassan, H. Halder, and K. S. Bennoor, “Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients,” Bangladesh Medical Research Council Bulletin, vol. 25, no. 1, pp. 11–13, 1999. View at Google Scholar · View at Scopus
  78. A. Tongia, S. K. Tongia, and M. Dave, “Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM),” Indian Journal of Physiology and Pharmacology, vol. 48, no. 2, pp. 241–244, 2004. View at Google Scholar · View at Scopus
  79. A. M. L. Dans, M. V. C. Villarruz, C. A. Jimeno et al., “The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies,” Journal of Clinical Epidemiology, vol. 60, no. 6, pp. 554–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Fuangchan, P. Sonthisombat, T. Seubnukarn et al., “Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients,” Journal of Ethnopharmacology, vol. 134, no. 2, pp. 422–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. C.-H. Tsai, E. C.-F. Chen, H.-S. Tsay, and C.-J. Huang, “Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial,” Nutrition Journal, vol. 11, no. 1, article 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Trakoon-osot, U. Sotanaphun, P. Phanachet, S. Porasuphatana, U. Udomsubpayakul, and S. Komindr, “Pilot study: hypoglycemic and antiglycation activities of bitter melon (Momordica charantia L.) in type 2 diabetic patients,” Journal of Pharmacy Research, vol. 6, no. 8, pp. 859–864, 2013. View at Publisher · View at Google Scholar
  83. D. W. Foster, “The role of the carnitine system in human metabolism,” Annals of the New York Academy of Sciences, vol. 1033, pp. 1–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. J.-Y. Kim, R. C. Hickner, R. L. Cortright, G. L. Dohm, and J. A. Houmard, “Lipid oxidation is reduced in obese human skeletal muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 279, no. 5, pp. E1039–E1044, 2000. View at Google Scholar · View at Scopus
  85. R. L. Dobbins, L. S. Szczepaniak, B. Bentley, V. Esser, J. Myhill, and J. McGarry, “Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats,” Diabetes, vol. 50, no. 1, pp. 123–130, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Perdomo, S. R. Commerford, A.-M. T. Richard et al., “Increased β-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation,” The Journal of Biological Chemistry, vol. 279, no. 26, pp. 27177–27186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. C. R. Bruce, A. J. Hoy, N. Turner et al., “Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance,” Diabetes, vol. 58, no. 3, pp. 550–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Schrauwen and M. Hesselink, “UCP2 and UCP3 in muscle controlling body metabolism,” The Journal of Experimental Biology, vol. 205, no. 15, pp. 2275–2285, 2002. View at Google Scholar · View at Scopus
  89. B. A. Henry, F. R. Dunshea, M. Gould, and I. J. Clarke, “Profiling postprandial thermogenesis in muscle and fat of sheep and the central effect of leptin administration,” Endocrinology, vol. 149, no. 4, pp. 2019–2026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. K.-I. Wakabayashi, M. Okamura, S. Tsutsumi et al., “The peroxisome proliferator-activated receptor γ/retinoid X receptor α heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop,” Molecular and Cellular Biology, vol. 29, no. 13, pp. 3544–3555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Vernochet, S. B. Peres, K. E. Davis et al., “C/EBPα and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor γ agonists,” Molecular and Cellular Biology, vol. 29, no. 17, pp. 4714–4728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. S. K. Panchal, H. Poudyal, A. Iyer et al., “High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats,” Journal of Cardiovascular Pharmacology, vol. 57, no. 5, pp. 611–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. A. D. Mooradian, “Dyslipidemia in type 2 diabetes mellitus,” Nature Clinical Practice Endocrinology & Metabolism, vol. 5, no. 3, pp. 150–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. T. J. Chahil and H. N. Ginsberg, “Diabetic dyslipidemia,” Endocrinology and Metabolism Clinics of North America, vol. 35, no. 3, pp. 491–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Chong, M. Naples, L. Federico et al., “Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia,” Atherosclerosis, vol. 185, no. 1, pp. 21–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Taghibiglou, F. Rashid-Kolvear, S. C. Van Iderstine et al., “Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance,” The Journal of Biological Chemistry, vol. 277, no. 1, pp. 793–803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Streicher, J. Kotzka, D. Müller-Wieland et al., “SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I,” The Journal of Biological Chemistry, vol. 271, no. 12, pp. 7128–7133, 1996. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Puigserver and B. M. Spiegelman, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator,” Endocrine Reviews, vol. 24, no. 1, pp. 78–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. R. B. Vega, J. M. Huss, and D. P. Kelly, “The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes,” Molecular and Cellular Biology, vol. 20, no. 5, pp. 1868–1876, 2000. View at Publisher · View at Google Scholar · View at Scopus
  100. M. B. Hock and A. Kralli, “Transcriptional control of mitochondrial biogenesis and function,” Annual Review of Physiology, vol. 71, pp. 177–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. B. B. Zhang, G. Zhou, and C. Li, “AMPK: an emerging drug target for diabetes and the metabolic syndrome,” Cell Metabolism, vol. 9, no. 5, pp. 407–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Cantó and J. Auwerx, “PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure,” Current Opinion in Lipidology, vol. 20, no. 2, pp. 98–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. B. N. Finck and D. P. Kelly, “PGC-1 coactivators: inducible regulators of energy metabolism in health and disease,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 615–622, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. D. G. Hardie, “AMPK: a key regulator of energy balance in the single cell and the whole organism,” International Journal of Obesity, vol. 32, no. S4, pp. S7–S12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Zong, J. M. Ren, L. H. Young et al., “AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 15983–15987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. P. M. Garcia-Roves, M. E. Osler, M. H. Holmström, and J. R. Zierath, “Gain-of-function R225Q mutation in AMP-activated protein kinase γ3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle,” The Journal of Biological Chemistry, vol. 283, no. 51, pp. 35724–35734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. C. Long, B. R. Barnes, M. Mahlapuu et al., “Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle,” Diabetologia, vol. 48, no. 11, pp. 2354–2364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. D. J. Peet, S. D. Turley, W. Ma et al., “Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα,” Cell, vol. 93, no. 5, pp. 693–704, 1998. View at Publisher · View at Google Scholar · View at Scopus
  109. B. P. Chaudhari, V. J. Chaware, Y. R. Joshi, and K. R. Biyani, “Hepatoprotective activity of hydroalcoholic extract of Momordica charantia Linn. leaves against carbon tetra chloride induced hepatopathy in rats,” International Journal of ChemTech Research, vol. 1, no. 2, pp. 355–358, 2009. View at Google Scholar · View at Scopus
  110. A. J. Thenmozhi and P. Subramanian, “Antioxidant potential of Momordica charantia in ammonium chloride-induced hyperammonemic rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 612023, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Zahra, M. A. Malik, M. S. Mughal, M. Arshad, and M. I. Sohail, “Hepatoprotective role of extracts of Momordica charantia L. in acetaminophen-induced toxicity in rabbits,” Journal of Animal and Plant Sciences, vol. 22, no. 2, pp. 273–277, 2012. View at Google Scholar · View at Scopus
  112. R. H. H. Ching, L. O. Y. Yeung, I. M. Y. Tse, W.-H. Sit, and E. T. S. Li, “Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring,” The Journal of Nutrition, vol. 141, no. 9, pp. 1664–1672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. S. K. Panchal, H. Poudyal, A. Iyer et al., “High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats,” Journal of Cardiovascular Pharmacology, vol. 57, no. 1, pp. 51–64, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. S. K. Mantena, A. L. King, K. K. Andringa, H. B. Eccleston, and S. M. Bailey, “Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases,” Free Radical Biology & Medicine, vol. 44, no. 7, pp. 1259–1272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Tappy and K.-A. Lê, “Metabolic effects of fructose and the worldwide increase in obesity,” Physiological Reviews, vol. 90, no. 1, pp. 23–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. K. L. Stanhope and P. J. Havel, “Fructose consumption: recent results and their potential implications,” Annals of the New York Academy of Sciences, vol. 1190, no. 1, pp. 15–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. M. M. Abdullah, N. N. Riediger, Q. Chen et al., “Effects of long-term consumption of a high-fructose diet on conventional cardiovascular risk factors in sprague-dawley rats,” Molecular and Cellular Biochemistry, vol. 327, no. 1-2, pp. 247–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. G. Morris-Stiff and A. E. Feldstein, “Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice,” Journal of Hepatology, vol. 53, no. 5, pp. 795–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Li, Q. Fang, F. Gao et al., “Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride,” Journal of Hepatology, vol. 53, no. 5, pp. 934–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. C. Day, T. Cartwright, J. Provost, and C. J. Bailey, “Hypoglycaemic effect of Momordica charantia extracts,” Planta Medica, vol. 56, no. 5, pp. 426–429, 1990. View at Publisher · View at Google Scholar · View at Scopus
  121. L. Ali, A. K. Azad Khan, M. I. Rouf Mamun et al., “Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats,” Planta Medica, vol. 59, no. 5, pp. 408–412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Srivastava, H. Venkatakrishna-Bhatt, Y. Verma, K. Venkaiah, and B. H. Raval, “Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation,” Phytotherapy Research, vol. 7, no. 4, pp. 285–289, 1993. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Sarkar, M. Pranava, and R. A. Marita, “Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes,” Pharmacological Research, vol. 33, no. 1, pp. 1–4, 1996. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Virdi, S. Sivakami, S. Shahani, A. C. Suthar, M. M. Banavalikar, and M. K. Biyani, “Antihyperglycemic effects of three extracts from Momordica charantia,” Journal of Ethnopharmacology, vol. 88, no. 1, pp. 107–111, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. J. A. O. Ojewole, S. O. Adewole, and G. Olayiwola, “Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats,” Cardiovascular Journal of South Africa, vol. 17, no. 5, pp. 227–232, 2006. View at Google Scholar · View at Scopus
  126. M. G. Sridhar, R. Vinayagamoorthi, V. A. Suyambunathan, Z. Bobby, and N. Selvaraj, “Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats,” British Journal of Nutrition, vol. 99, no. 4, pp. 806–812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Chaturvedi, “Antidiabetic potentials of momordica charantia: multiple mechanisms behind the effects,” Journal of Medicinal Food, vol. 15, no. 2, pp. 101–107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. I. Ahmed, E. Adeghate, E. Cummings, A. K. Sharma, and J. Singh, “Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat,” Molecular and Cellular Biochemistry, vol. 261, no. 1, pp. 63–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. M. F. Mahomoodally, A.-G. Fakim, and A. H. Subratty, “Momordica charantia extracts inhibit uptake of monosaccharide and amino acid across rat everted gut sacs in-vitro,” Biological and Pharmaceutical Bulletin, vol. 27, no. 2, pp. 216–218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. Z. Ahmad, K. F. Zamhuri, A. Yaacob et al., “In vitro anti-diabetic activities and chemical analysis of polypeptide-k and oil isolated from seeds of Momordica charantia (bitter gourd),” Molecules, vol. 17, no. 8, pp. 9631–9640, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. N. G. Sahib, A. A. Hamid, N. Saari, F. Abas, M. S. P. Dek, and M. Rahim, “Anti-pancreatic lipase and antioxidant activity of selected tropical herbs,” International Journal of Food Properties, vol. 15, no. 3, pp. 569–578, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. Y. Oishi, T. Sakamoto, H. Udagawa et al., “Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction,” Bioscience, Biotechnology and Biochemistry, vol. 71, no. 3, pp. 735–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Miura, C. Itoh, N. Iwamoto et al., “Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice,” Journal of Nutritional Science and Vitaminology, vol. 47, no. 5, pp. 340–344, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. C.-C. Shih, C.-H. Lin, W.-L. Lin, and J.-B. Wu, “Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 82–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. E. Cummings, H. S. Hundal, H. Wackerhage et al., “Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes,” Molecular and Cellular Biochemistry, vol. 261, no. 1, pp. 99–104, 2004. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Kumar, S. Balaji, T. S. Uma, and P. K. Sehgal, “Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPARγ and PI3K,” Journal of Ethnopharmacology, vol. 126, no. 3, pp. 533–537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. B. W. C. Roffey, A. S. Atwal, T. Johns, and S. Kubow, “Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells,” Journal of Ethnopharmacology, vol. 112, no. 1, pp. 77–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. I. Ahmed, E. Adeghate, A. K. Sharma, D. J. Pallot, and J. Singh, “Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat,” Diabetes Research and Clinical Practice, vol. 40, no. 3, pp. 145–151, 1998. View at Publisher · View at Google Scholar · View at Scopus
  139. D. Sathishsekar and S. Subramanian, “Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats,” Biological and Pharmaceutical Bulletin, vol. 28, no. 6, pp. 978–983, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. R. M. Hafizur, N. Kabir, and S. Chishti, “Modulation of pancreatic β-cells in neonatally streptozotocin-induced type 2 diabetic rats by the ethanolic extract of Momordica charantia fruit pulp,” Natural Product Research, vol. 25, no. 4, pp. 353–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. N. Singh and M. Gupta, “Regeneration of β cells in islets of Langerhans of pancreas of alloxan diabetic rats by acetone extract of Momordica charantia (Linn.) (bitter gourd) fruits,” Indian Journal of Experimental Biology, vol. 45, no. 12, pp. 1055–1062, 2007. View at Google Scholar · View at Scopus
  142. S. Yibchok-Anun, S. Adisakwattana, C. Y. Yao, P. Sangvanich, S. Roengsumran, and W. H. Hsu, “Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities,” Biological and Pharmaceutical Bulletin, vol. 29, no. 6, pp. 1126–1131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. A. C. Keller, J. Ma, A. Kavalier, K. He, A.-M. B. Brillantes, and E. J. Kennelly, “Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro,” Phytomedicine, vol. 19, no. 1, pp. 32–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. Q. Chen, L. L. Y. Chan, and E. T. S. Li, “Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet,” The Journal of Nutrition, vol. 133, no. 4, pp. 1088–1093, 2003. View at Google Scholar · View at Scopus
  145. H.-Y. Lo, T.-Y. Ho, C. Lin, C.-C. Li, and C.-Y. Hsiang, “Momordica charantia and its novel polypeptide regulate glucose homeostasis in mice via binding to insulin receptor,” Journal of Agricultural and Food Chemistry, vol. 61, no. 10, pp. 2461–2468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. D. L. Clouatre, S. N. Rao, and H. G. Preuss, “Bitter melon extracts in diabetic and normal rats favorably influence blood glucose and blood pressure regulation,” Journal of Medicinal Food, vol. 14, no. 12, pp. 1496–1504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. C.-H. Tsai, E. C.-F. Chen, H.-S. Tsay, and C.-J. Huang, “Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial,” Nutrition Journal, vol. 11, article 4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. S.-J. Wu and L.-T. Ng, “Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan,” LWT: Food Science and Technology, vol. 41, no. 2, pp. 323–330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. R. Horax, N. Hettiarachchy, and P. Chen, “Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe),” Journal of Agricultural and Food Chemistry, vol. 58, no. 7, pp. 4428–4433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. R. Kumar, S. Balaji, R. Sripriya, N. Nithya, T. S. Uma, and P. K. Sehgal, “In vitro evaluation of antioxidants of fruit extract of Momordica charantia L. on fibroblasts and keratinocytes,” Journal of Agricultural and Food Chemistry, vol. 58, no. 3, pp. 1518–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. L. Leung, R. Birtwhistle, J. Kotecha, S. Hannah, and S. Cuthbertson, “Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review,” British Journal of Nutrition, vol. 102, no. 12, pp. 1703–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. C. P. Ooi, Z. Yassin, and T. A. Hamid, “Momordica charantia for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 8, Article ID CD007845, 2012. View at Publisher · View at Google Scholar